In this issue:
PFS benefit to apatinib/pegylated liposomal doxorubicin in advanced ovarian cancer
Multiomic characterisation of HGSOC enables high-resolution patient stratification
Addition of olaparib to front-line maintenance confers PFS2 advantage in HRD disease
EMPOWER CERVICAL-1: Patient-reported outcomes favour cemiplimab
Management of oligometastatic disease during PARP inhibitor therapy
Talazoparib plus avelumab for pMMR endometrial cancer
Letrozole and abemaciclib promising for oestrogen receptor–positive endometrial cancer
Ten-year survival after chemotherapy in stage 3 ovarian cancer
Please login below to download this issue (PDF)